je.st
news
Tag: merck
Merck Announces FDA Acceptance of Biologics License Application for Investigational House Dust Mite Sublingual Allergy Immunotherapy Tablet
2016-04-12 23:00:22| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J. Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for MK-8237, Mercks house dust mite sublingual allergy immunotherapy (SLIT) tablet. Language: English read more
Tags: house
application
license
acceptance
Merck, employees provide wildfire relief
2016-04-12 17:45:05| Beef
The fires are still smoldering, but the impact will be felt for years to come. read more
Tags: provide
employees
relief
merck
Merck to Hold First-Quarter 2016 Sales and Earnings Conference Call on May 5
2016-04-08 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Thursday, May 5. During the call, company executives will provide an overview of Mercks performance for the quarter. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Claire Gillespie, 267-305-0932orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More Than 30 Data Presentations at ECCMID 2016
2016-04-07 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more than 30 scientific data presentations on the companys established and investigational infectious disease medicines and vaccines at this years 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12 in Amsterdam, Netherlands. Language: English Contact: MerckMedia:Doris Li, 908-246-5701Robert Consalvo, 908-295-0928orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
commitment
highlights
ongoing
Merck to Present New Data for KEYTRUDA (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting
2016-04-06 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Data Evaluating KEYTRUDA as a Single Agent and in Novel Combinations Across a Wide Range of Cancers to Be Presented KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new research investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in multiple tumor types, both as a single agent and in combination with other therapies, will be presented at this years American Association for Cancer Research (AACR) Annual Meeting in New Orleans, April 16 20. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestor:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
research
present
american
Sites : [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] next »